3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Squamous Cell Carcinoma of Head and Neck
11
Nasopharyngeal Carcinoma
6
Oropharyngeal Neoplasms
5
Prostatic Neoplasms
4
Laryngeal Neoplasms
4
Carcinoma
4
Mouth Neoplasms
3
Hypopharyngeal Neoplasms
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Mesothelioma
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Anus Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Tongue Neoplasms
1
Stomatitis
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Salivary Gland Neoplasms
1
PSA Level Greater Than Two
1
Oligodendroglioma
1
Mesothelioma, Malignant
1
Meningioma
1
Lymphoma, Follicular
1
Lymphoid Interstitial Pneumonia
1
Locally Advanced Cervical Adenocarcinoma
1
HIV Infections
1
Glioma
1
Glioblastoma
1
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Radiotherapy, Intensity-Modulated
×
30 days
×
Clear all
No trials found.